This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of cabergoline
PDMED_CABERGOLINE
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
476 |
4. Check minimum number of events
Min. number of events
3
|
476 |
5. Include endpointsNone |
476 |
6. Filter based on genotype QC (FinnGen only) |
476 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Use of cabergoline
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 476 | 276 | 200 |
| Unadjusted period prevalence (%) | 0.09 | 0.09 | 0.09 |
| Median age at first event (years) | 46.59 | 39.42 | 56.48 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 410
- Matched controls
- 4098
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N04BC06
ATC
cabergoline; oral (dopamine agonists)
+∞
323.0
410
5
E22.1
ICD-10 Finland
Hyperprolactinaemia
454.0
293.6
263
16
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
305.9
239.8
224
16
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
177.2
162.6
162
15
G02CB01
ATC
bromocriptine; systemic
48.7
85.3
103
28
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
37.4
65.7
84
28
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
25.3
63.2
90
45
G20
ICD-10 Finland
Parkinson disease
29.8
62.0
84
35
N04BD01
ATC
selegiline; oral
71.1
58.5
66
11
G02CB03
ATC
cabergoline; oral (prolactine inhibitors)
84.5
47.2
52
7
H02AB09
ATC
hydrocortisone; systemic
23.5
44.3
64
32
N04BA03
ATC
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
79.1
44.1
49
7
AA4CM
NOMESCO Finland
Extensive MRI examination of sella turcica with 3 Tesla magnet
414.0
38.7
38
*
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
66.6
36.9
42
7
N04BC05
ATC
pramipexole; oral
9.2
36.7
81
107
N04BX02
ATC
entacapone; oral
131.2
34.3
36
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
59.6
32.9
38
7
AA4BG
NOMESCO Finland
MRI examination of sella turcica with high intensity magnet
95.5
32.3
35
*
N04BC04
ATC
ropinirole; oral
41.6
30.8
38
10
E23.00
ICD-10 Finland
Panhypopituitarism
61.5
29.6
34
6
N04BD02
ATC
rasagiline; oral
80.8
27.2
30
*
N87
ICPC
Parkinsonism
40.3
24.3
30
8
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
7.6
23.3
56
83
193
Kela drug reimbursment
Rasagiline
55.3
22.4
26
5
F02.39*G20
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
121.5
21.8
23
*
H03AA01
ATC
levothyroxine sodium; systemic
3.2
20.5
128
504
E23.04
ICD-10 Finland
Hypogonadotropic hypogonadism
33.1
19.5
25
8
G02CB04
ATC
quinagolide; oral
198.7
18.7
19
*
N91.1
ICD-10 Finland
Secondary amenorrhoea
13.2
18.4
32
26
XCK00
NOMESCO Finland
Perimetry
5.3
17.0
54
115
E22.0
ICD-10 Finland
Acromegaly and pituitary gigantism
66.2
16.9
19
*
D44.3
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Pituitary gland
66.2
16.9
19
*
N03AE01
ATC
clonazepam; systemic
5.7
15.2
44
84
N04AA02
ATC
biperiden; systemic
13.1
15.1
26
21
N04BC01
ATC
bromocriptine; oral
+∞
12.6
12
*
N04BB01
ATC
amantadine; oral
11.0
12.4
23
22
N04BC02
ATC
pergolide; oral
48.1
11.9
14
*
D352, E221
ICD-10 Finland
NA
+∞
11.5
11
*
H01CB02
ATC
octreotide; parenteral
41.1
10.0
12
*
N04BC09
ATC
rotigotine; transdermal
56.3
9.7
11
*
E22.9
ICD-10 Finland
Hyperfunction of pituitary gland, unspecified
102.3
9.5
10
*
H01CB03
ATC
lanreotide; parenteral
102.3
9.5
10
*
N06DA03
ATC
rivastigmine; oral, transdermal
5.7
9.1
25
46
G03DB01
ATC
dydrogesterone; oral
2.6
8.8
67
285
2273A
ICD-9 Finland
Benign neoplasm of other endocrine glands and related structures, Pituitary gland and craniopharyngeal duct (pouch)
+∞
8.4
8
*
H02AA02
ATC
fludrocortisone; oral
11.1
8.4
15
14
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.5
8.3
69
308
E34.9
ICD-10 Finland
Endocrine disorder, unspecified
34.1
8.1
10
*
D44.8
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Pluriglandular involvement
34.1
8.1
10
*
AAG20
NOMESCO Finland
Stereotactic intracranial implantation of electrodes
34.1
8.1
10
*
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
11.1
7.8
14
13
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
3.1
7.8
41
140
ZXC86
NOMESCO Finland
Use of endoscopic device
15.4
7.8
12
8
N64.3
ICD-10 Finland
Galactorrhoea not associated with childbirth
45.9
7.7
9
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
5.3
7.7
22
43
N05AX08
ATC
risperidone; systemic
3.1
7.6
40
136
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
12.2
7.6
13
11
E23.05
ICD-10 Finland
Lack of TSH
20.4
7.2
10
5
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
4.6
7.1
23
52
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
2.9
6.7
39
142
H53.4
ICD-10 Finland
Visual field defects
5.9
6.5
17
30
3320A
ICD-9 Finland
Parkinson's disease, Paralysis agitans
70.9
6.4
7
*
E24.0
ICD-10 Finland
Pituitary-dependent Cushing disease
70.9
6.4
7
*
AA4DG
NOMESCO Finland
Very extensive MRI examination of sella turcica with high intensity magnet
70.9
6.4
7
*
E23.6
ICD-10 Finland
Other disorders of pituitary gland
70.9
6.4
7
*
2542
FHL
Transasal hypophysectomy
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
281
204
32.18
307.65
7.6
1.3
537.99
285.26
mu/l
1.92
270
184
269
342
16.79
222.38
4.7
1.9
365.47
373.36
nmol/l
0.25
262
316
141
146
13.30
128.26
1.9
1.3
6.01
10.03
u/l
2.27
116
121
138
299
6.09
64.04
6.5
2.2
11.29
13.09
nmol/l
1.79
131
274
69
88
9.00
52.02
1.6
1.6
0.37
0.39
nmol/l
0.09
53
74
105
240
5.33
44.86
1.8
1.3
14.77
22.59
iu/l
1.80
84
208
33
5
70.68
29.30
1.8
1.2
—
—
—
0
0
382
2872
2.67
16.69
6.8
3.9
14.82
14.56
pmol/l
1.18
371
2633
67
252
2.93
13.32
2.5
3.7
4.49
4.62
pmol/l
0.53
62
221
20
36
5.76
10.78
5.8
3.3
5.44
7.81
nmol/l
0.20
20
36
211
1443
1.83
9.30
5.9
5.7
1.22
1.21
mmol/l
0.49
201
1321
18
35
5.31
8.95
1.5
1.2
—
—
—
0
0
224
1605
1.75
8.10
7.1
6.6
1.22
1.21
mmol/l
0.81
189
1359
393
3440
1.82
5.76
6.6
4.6
1.68
1.82
mu/l
2.04
373
3189
11
32
3.50
3.35
3.2
2.2
19.61
16.84
mu/l
0.13
11
32
44
251
1.83
3.30
2.7
2.3
7653.12
2984.33
u/l
0.41
15
105
407
3749
1.59
3.18
15.5
13.9
139.99
139.56
mmol/l
4.12
402
3631
55
347
1.66
2.93
3.1
3.1
—
—
—
0
0
12
41
2.98
2.88
1.4
1.4
—
—
—
0
0
406
3763
1.54
2.81
15.8
13.9
3.90
3.96
mmol/l
4.36
401
3635
18
81
2.27
2.57
1.3
1.3
2.63
2.81
ug/l
0.11
18
74
378
3477
1.42
2.50
12.3
11.2
88.07
87.02
ml/min/173m2
0.45
344
2827
6
12
5.05
2.41
2.0
1.4
50.50
65.05
ug/l
—
6
12
239
2058
1.32
2.39
4.3
4.5
6.25
6.55
mmol/l
1.88
227
1872
12
270
0.43
2.29
2.6
2.2
—
20.74
—
0
17
37
225
1.70
2.29
7.1
3.9
102.98
81.18
ng/l
0.34
32
205
306
2741
1.33
2.26
6.3
7.1
72.14
74.86
u/l
0.86
288
2576
11
244
0.44
2.04
1.3
1.2
—
39.98
—
0
11
173
1452
1.30
2.00
2.9
2.3
74.85
73.65
nmol/l
0.24
164
1330
7
23
3.07
1.80
1.7
1.6
—
—
—
0
0
118
958
1.31
1.72
3.1
2.8
0.25
0.29
e6/l
0.18
85
726
20
340
0.57
1.70
1.3
1.9
—
—
—
0
0
5
131
0.38
1.65
1.4
2.5
—
—
—
0
0
63
823
0.73
1.54
3.7
3.5
1.02
1.02
kg/l
—
9
113
109
896
1.28
1.44
1.5
1.6
1.43
1.40
mmol/l
0.14
99
775
46
620
0.71
1.37
1.1
1.2
2.26
7.68
u/ml
2.01
16
249
47
631
0.72
1.37
1.2
1.3
23.46
28.13
iu/ml
0.18
11
203
25
379
0.64
1.37
6.6
7.1
—
—
—
0
0
127
1073
1.25
1.33
3.1
2.9
112.83
116.42
e6/l
0.01
96
825
67
525
1.32
1.27
2.4
2.7
3.00
2.37
e6/l
0.24
41
287
152
1326
1.21
1.17
1.9
1.9
96.68
95.09
pmol/l
0.16
80
718
7
137
0.50
1.11
1.0
1.5
1.39
1.18
g/l
—
7
129
9
165
0.54
1.10
1.1
2.0
—
—
—
0
0
9
46
1.97
1.04
1.1
1.3
0.57
0.50
nmol/l
—
9
41
75
901
0.80
0.99
1.6
1.6
—
—
—
0
0
15
92
1.65
0.98
1.5
1.2
—
—
—
0
0
345
3274
1.20
0.97
5.4
5.1
38.23
39.25
mmol/mol
1.31
329
3090
21
295
0.70
0.84
3.2
4.8
2.01
30.24
ug/l
1.04
14
246
10
57
1.77
0.84
1.7
2.1
13.50
13.13
%
—
10
57
91
783
1.20
0.81
1.4
1.5
20.76
20.19
nmol/l
0.13
83
684
33
427
0.76
0.80
1.4
2.0
—
—
—
0
0
55
450
1.25
0.79
2.4
2.3
23.00
23.73
%
0.16
49
396
0
26
0.00
0.78
0.0
1.2
—
—
—
0
0
7
38
1.85
0.74
20.7
16.4
1657.71
1450.13
nmol/l
—
7
38
51
420
1.24
0.71
1.9
2.6
3.99
8.36
umol/l
4.33
42
360
75
866
0.84
0.68
3.1
3.1
920.65
1230.60
ng/l
0.62
63
722
18
247
0.72
0.66
1.3
1.2
113.39
245.64
u/ml
0.67
18
223
22
164
1.36
0.63
1.3
1.6
—
—
—
0
0
64
547
1.20
0.63
2.5
2.5
0.89
0.85
e6/l
0.03
38
307
117
1054
1.15
0.61
4.6
4.5
1.65
2.41
ug/l
1.42
107
947
0
20
0.00
0.60
0.0
1.2
—
1691.95
—
0
20
0
20
0.00
0.60
0.0
3.1
—
—
—
0
0
20
265
0.74
0.60
1.2
1.5
—
—
—
0
0
61
707
0.84
0.59
1.7
1.7
442.63
436.25
pmol/l
0.05
56
610
17
123
1.40
0.58
1.6
1.8
—
—
—
0
0
5
86
0.58
0.56
4.8
1.6
—
—
—
0
0
5
87
0.57
0.56
2.2
2.1
25.44
23.80
mmol/l
—
5
76
161
1736
0.89
0.56
3.9
4.2
—
—
—
0
0
5
89
0.56
0.56
1.0
1.3
—
37.02
—
0
8
123
1119
1.13
0.56
2.7
3.3
2.33
2.35
mmol/l
0.40
107
996
18
133
1.37
0.56
2.7
2.0
—
—
—
0
0
120
1092
1.13
0.54
2.3
2.5
57.26
54.49
u/l
0.32
107
1018
269
2815
0.90
0.54
3.4
3.5
—
—
—
0
0
390
3994
0.87
0.53
9.6
9.3
24.74
26.57
u/l
1.38
376
3871
192
1799
1.11
0.53
2.6
2.8
94.70
108.93
ug/l
0.49
182
1683
16
214
0.74
0.52
1.1
1.0
—
—
—
0
0
7
110
0.63
0.49
1.1
1.3
—
2.56
—
0
5
17
128
1.34
0.48
1.1
1.5
—
—
—
0
0
18
137
1.33
0.48
1.6
1.3
—
—
—
0
0
14
188
0.74
0.48
1.6
1.6
—
—
—
0
0
85
942
0.88
0.47
4.6
4.0
5.21
10.51
mg/mmol
1.21
53
611
64
720
0.87
0.44
1.4
1.4
—
—
—
0
0
82
907
0.88
0.44
2.5
2.4
336.53
6452.52
umol/l
3.54
72
795
6
92
0.65
0.42
1.3
1.2
—
—
—
0
0
6
93
0.64
0.42
1.5
1.5
—
—
—
0
0
8
57
1.41
0.42
2.4
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
57
504
1.15
0.41
1.9
1.9
29.47
29.71
s
0.08
57
492
0
17
0.00
0.40
0.0
1.0
—
—
—
0
0
22
270
0.81
0.40
1.9
2.4
6.21
7.92
ug/l
0.28
17
245
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.0
—
505.30
—
0
10
0
18
0.00
0.40
0.0
1.0
—
38.04
—
0
8
68
610
1.13
0.40
3.0
3.4
14.18
229.52
ng/l
3.83
44
419
34
398
0.84
0.39
3.7
6.6
105.21
104.47
mmol/l
0.67
34
386
31
261
1.20
0.39
2.1
2.4
77.38
70.51
ml/min/173m2
0.50
12
111
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
9
66
1.37
0.38
1.4
1.3
—
—
—
0
0
9
66
1.37
0.38
1.4
1.3
—
—
—
0
0
17
135
1.27
0.35
1.7
1.7
—
—
—
0
0
6
44
1.37
0.34
2.0
1.1
—
—
—
0
0
10
74
1.36
0.32
2.8
3.6
4.49
4.38
e9/l
—
10
74
67
610
1.11
0.32
2.5
2.8
0.70
0.79
ug/l
0.44
42
373
206
2145
0.93
0.31
7.9
8.8
4.00
4.08
e9/l
0.23
192
1899
91
845
1.10
0.30
3.4
4.1
25.81
21.58
%
1.46
44
375
10
75
1.34
0.30
3.3
4.1
61.60
56.59
%
—
10
75
66
603
1.11
0.30
1.7
1.7
1142.35
1183.53
nmol/l
0.14
55
461
12
93
1.30
0.30
2.8
1.5
—
—
—
0
0
62
678
0.90
0.29
2.0
2.0
—
—
—
0
0
8
107
0.74
0.29
1.4
1.1
—
—
—
0
0
149
1416
1.08
0.29
4.4
4.9
35.76
36.23
g/l
0.50
140
1328
356
3628
0.93
0.28
4.3
3.9
1.41
1.45
mmol/l
1.10
342
3403
68
738
0.91
0.28
2.1
2.2
—
—
—
0
0
349
3557
0.93
0.27
14.7
13.4
39.99
40.28
%
0.26
260
2764
54
590
0.90
0.26
2.6
2.8
2.45
2.43
mmol/l
0.51
42
513
6
81
0.74
0.24
8.3
4.4
24.50
29.19
mg/l
—
6
64
58
534
1.10
0.24
1.9
1.8
—
—
—
0
0
364
3698
0.93
0.23
4.6
4.3
2.81
2.79
mmol/l
0.15
348
3460
26
228
1.15
0.23
1.7
1.6
—
—
—
0
0
7
95
0.73
0.22
1.0
2.9
—
—
—
0
0
359
3646
0.94
0.22
4.4
3.9
4.65
4.67
mmol/l
0.10
342
3434
187
1807
1.06
0.22
5.7
5.8
28.75
28.26
%
0.29
178
1700
185
1788
1.06
0.21
5.1
5.7
56.86
57.42
%
0.32
177
1691
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
190
1839
1.06
0.21
3.4
3.3
0.00
0.00
estimate
0.00
47
378
25
282
0.88
0.21
3.8
3.6
5.89
5.74
kpa
0.45
25
274
0
13
0.00
0.21
0.0
3.4
—
—
—
0
0
0
13
0.00
0.21
0.0
3.4
—
—
—
0
0
191
1852
1.05
0.20
4.8
4.6
0.00
0.00
estimate
0.50
49
385
19
165
1.16
0.19
3.8
8.9
24.07
24.44
mmol/l
0.34
19
153
6
52
1.16
0.19
2.5
1.4
—
—
—
0
0
6
52
1.16
0.19
2.5
1.4
—
—
—
0
0
6
52
1.16
0.19
2.5
1.4
—
—
—
0
0
6
53
1.13
0.18
2.5
1.4
—
—
—
0
0
6
53
1.13
0.18
2.5
1.4
—
—
—
0
0
6
53
1.13
0.18
2.5
1.4
—
—
—
0
0
36
393
0.91
0.18
1.5
1.5
—
—
—
0
0
86
903
0.94
0.17
1.2
1.3
1.86
1.50
u/ml
0.17
25
264
5
70
0.71
0.17
1.8
1.4
—
—
—
0
0
34
370
0.91
0.16
21.3
21.8
1.06
1.27
inr
—
5
53
267
2720
0.96
0.16
3.4
3.8
9.73
10.60
mm/h
0.59
251
2521
6
80
0.75
0.15
8.3
4.3
—
2.69
—
0
11
9
80
1.13
0.15
1.2
1.2
—
—
—
0
0
9
80
1.13
0.15
2.9
1.4
569.78
141.82
e6/l
—
9
68
9
80
1.13
0.15
2.9
1.3
69.44
5.89
e6/l
—
9
65
94
901
1.05
0.15
2.2
2.0
2.66
2.87
mg/l
0.54
78
773
7
87
0.80
0.14
3.1
1.6
—
—
—
0
0
25
274
0.91
0.14
4.3
6.4
1.13
1.25
mmol/l
0.45
25
264
384
3803
1.05
0.14
12.4
12.7
21.08
21.81
mg/l
0.17
305
2982
9
107
0.84
0.13
1.2
1.3
—
—
—
0
0
15
168
0.89
0.12
1.5
1.7
—
—
—
0
0
29
269
1.08
0.11
5.8
7.0
7.85
8.91
mmol/l
0.42
29
255
134
1305
1.04
0.11
2.7
3.5
24.72
40.66
ng/l
1.44
80
816
11
126
0.87
0.11
1.3
1.2
—
—
—
0
0
11
126
0.87
0.11
1.3
1.2
—
—
—
0
0
36
341
1.06
0.09
3.6
8.4
0.50
1.03
mmol/l
0.42
22
264
34
322
1.06
0.08
2.0
2.3
26.37
29.35
u/l
0.72
27
269
245
2420
1.03
0.08
4.6
4.1
—
1660.50
—
0
42
129
1263
1.03
0.08
2.6
3.1
31.98
31.06
u/l
0.05
122
1213
5
65
0.77
0.08
1.0
1.0
—
2.02
—
0
28
6
71
0.84
0.07
1.2
1.2
—
—
—
0
0
104
1016
1.03
0.07
3.1
3.1
8.62
7.91
mmol/l
0.51
94
865
7
83
0.84
0.07
4.0
1.6
0.81
0.86
nmol/l
—
7
74
43
413
1.05
0.07
1.5
1.6
—
—
—
0
0
21
224
0.93
0.07
1.4
1.5
—
—
—
0
0
103
1009
1.03
0.06
3.5
3.5
0.00
0.00
estimate
0.50
49
375
10
111
0.90
0.06
5.5
2.3
—
—
—
0
0
15
139
1.08
0.05
5.7
3.5
24.33
24.05
mmol/l
0.13
15
127
13
141
0.92
0.05
1.3
1.5
—
—
—
0
0
25
238
1.05
0.05
1.3
1.4
—
—
—
0
0
31
298
1.04
0.04
1.3
1.2
62.82
150.82
iu/ml
2.27
13
121
17
180
0.94
0.04
1.4
1.7
—
—
—
0
0
20
210
0.95
0.03
1.4
1.4
—
—
—
0
0
20
210
0.95
0.03
1.4
1.4
—
—
—
0
0
189
1875
1.01
0.03
3.5
3.4
0.00
0.00
estimate
0.00
47
369
20
209
0.96
0.03
1.4
1.4
—
—
—
0
0
20
209
0.96
0.03
1.4
1.4
—
—
—
0
0
349
3503
0.99
0.03
4.0
3.6
1.29
1.27
mmol/l
0.24
333
3279
10
108
0.92
0.03
1.5
2.1
362.00
358.93
ug/l
—
10
102
351
3518
0.99
0.01
4.5
4.0
5.72
5.83
mmol/l
1.30
328
3272
17
175
0.97
0.00
1.3
1.4
227.00
247.38
miu/ml
—
8
92
36
363
0.99
0.00
1.6
1.7
—
—
—
0
0
36
363
0.99
0.00
1.6
1.8
—
—
—
0
0
21
209
1.01
0.00
1.6
1.5
—
—
—
0
0
263
2632
1.00
0.00
3.2
2.9
37.23
42.18
u/l
0.82
253
2498
86
859
1.00
0.00
2.7
2.2
—
—
—
0
0
148
1483
1.00
0.00
3.5
3.4
—
—
—
0
0
181
1815
1.00
0.00
5.1
6.0
9.05
11.17
umol/l
4.89
167
1719
82
824
0.99
0.00
1.5
1.7
1.09
1.08
mg/l
0.00
58
617
5
54
0.93
0.00
1.2
1.1
19.45
13.90
u/l
—
5
49
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
8
87
0.92
0.00
2.6
1.3
410.13
397.17
mg/l
—
8
82
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
5
52
0.96
0.00
1.0
2.0
—
1552.00
—
0
5
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
1.31
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
7
69
1.01
0.00
1.3
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
5
49
1.02
0.00
7.8
4.8
302.00
355.36
umol/l
—
5
43
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
8
86
0.93
0.00
2.3
1.4
—
—
—
0
0
8
79
1.01
0.00
1.7
1.4
—
116.06
—
0
17
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: PDMED_CABERGOLINE – Use of cabergoline
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).